CaptainCobec, nice. Affitech stock action could indeed be reflecting an amazing discovery: which anti-phospolipid antibodies have the greatest effect against cancers and viruses. A panolpy of Anti-PhosphoLipid MABs are probably being studies by Affitec, that is, all the potentially therapeutic phospholipid MABs current technology can detect. Affitech has milestone goals with PPHM. The first appears to have been handled easily, that of decoding for mass synthesis a humanized form of Bavi. That done, Affitech was next tasked with sorting through myriad phospholipid MABs for therapeutically potent agents. And now they may have closed in on the second milestone. Maybe.
The above is only one possibility, and I may be getting way too far in front of myself.
We can mass-produce fully humanized Bavi. That is know.
Affitech said it has the recipe.
Avid can cook the MAB broth.
If chimeric Bavi, PPHM's anti-PS MAB--made of mouse and human parts--is significantly useful in the short-term, then the outlook for oral fully-humanized Bavi is excellent.
Other possibilities for the price rise?
Russell index buying?
The biotech I watch were way up today.
Numbers for Bavi-chimeric are being crunched right now for release in the next few days. Exciting stuff.
Efforts of PPHM lab scientists have gained scientific community respect and attention, and the perception out there is one of "definite possibility" for PPHM agents. Why? Little downside:the apparent paucity of side-effects; enormous upside.
Glad a bought a thousand shares a week after the split.
Market Data 
Markets 
AI
